Esophageal Cancer Care

What is esophageal cancer?

Esophageal cancer begins in the tube that carries food from the throat to the stomach. The two main cell types are adenocarcinoma and squamous-cell carcinoma. The cell type, location, stage, biomarkers, and a patient's overall health all influence the care plan.

Symptoms may include difficulty swallowing, a feeling that food sticks, painful swallowing, unexplained weight loss, persistent chest discomfort, or anemia. These symptoms do not always mean cancer, but they should be evaluated.

Barrett’s esophagus and cancer risk

Barrett’s esophagus is a change in the lining of the lower esophagus associated with long-standing reflux. It increases the risk of adenocarcinoma, but it is not itself cancer. Most people with Barrett’s do not develop cancer.

Screening depends on reflux history and other risk factors; not everyone with heartburn needs a screening endoscopy. After diagnosis, biopsy findings and the length of the affected area help guide follow-up. ^[3]

Selected precancerous changes and very early cancers confined to the lining may be treated through an endoscope. Pathology and assessment of spread determine whether this is appropriate. ^[3]

Read more about reflux and Barrett’s follow-up or explore the esophageal cancer treatment guide.

Where can it occur?

Location is one part of the picture. The tumor's depth, lymph nodes, distant spread, and histology are equally important.

Confirming the diagnosis and stage

Diagnosis usually begins with upper endoscopy and biopsy. Once cancer is confirmed, evaluation commonly includes CT of the chest and abdomen, PET/CT, and endoscopic ultrasound. Suspicious lymph nodes may be sampled when the result would change treatment. Additional tests are selected according to the tumor's location and imaging findings.

Our office reviews the actual images, endoscopy and pathology reports, identifies gaps, and helps patients understand where surgery may—or may not—fit.

Why testing the tumor matters

For advanced cancer, laboratory tests on the tumor help the oncology team choose immunotherapy or targeted treatment. These tests look for features of the cancer that may make a particular treatment useful:

• HER2: a protein that can identify certain adenocarcinomas for HER2-directed treatment.
• PD-L1: a marker that helps assess the potential benefit of immunotherapy.
• Mismatch repair (MMR) or microsatellite instability (MSI): tests for problems in the tumor’s DNA-repair system that may influence immunotherapy choices.
• CLDN18.2: a potential treatment target in appropriate stomach or gastroesophageal-junction adenocarcinomas.

Which tests and treatments apply depends on the cancer’s cell type, location, stage, prior treatment, and your overall health. A drug used for one tumor type is not automatically suitable for another. Ask the oncology team which results are available and how they affect your plan. ^[4]

Why coordinated care matters

Esophageal cancer rarely belongs to one specialist. Some patients receive chemotherapy, radiation, or both before an operation; others follow a different sequence. Nutrition and recovery planning begin before treatment, not after it.

We work closely with medical oncologists and radiation oncologists to create a patient-specific sequence and help coordinate care with the specialists and hospitals available across the Merrimack Valley and Southern New Hampshire. The aim is efficient communication and a clear next step—not a one-size-fits-all plan.